L'intérêt à découvert pour BigCommerce Holdings donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de BigCommerce Holdings. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

BigCommerce Holdings (NASDAQ:BIGC) Stock, Rapport sur les intérêts à découvert

BigCommerce Holdings

BigCommerce Holdings Inc is engaged in offering Software-as-a-service (SaaS) e-commerce platform. The company's SaaS platform engages in the creation of online stores by delivering a combination of ease-of-use, enterprise functionality, and flexibility. It powers both the customers' branded ecommerce stores and their cross-channel connections to popular online marketplaces, social networks, and offline point-of-sale systems. The group operates in a single segment covering geographical areas of Americas-U.S.; Americas-other; EMEA; and APAC, of which majority of revenue is generated from Americas-U.S.

BigCommerce Holdings, Inc. - Series 1 Common Stock

BigCommerce Holdings Inc

Zomedica Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZOM#NYSE">ZOM</a>) shares are trading higher on Thursday. The company disclosed the expansion of its <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/ac41160353/zomedica-announces-expansion-of-exclusive-equine-distribution-agreement-with-grovet-in-europe" rel="noreferrer noopener">distribution partnership with </a><a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/ac41160353/zomedica-announces-expansion-of-exclusive-equine-distribution-agreement-with-grovet-in-europe" rel="noreferrer noopener">Grovet</a>.
The updated agreement grants Grovet exclusive equine distribution rights for Zomedica&#8217;s PulseVet and TRUFORMA product platforms across 27 countries in Europe.
The updated agreement gives Grovet exclusive rights to distribute Zomedica&#8217;s PulseVet and TRUFORMA equine products in 27 European countries, including Germany, France, and Spain. Distribution in Italy and the U.K. will be non-exclusive.
Related: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/08/40366111/zomedica-taps-into-costa-rica-with-strategic-partnership-with-sire-veterinario" rel="noreferrer noopener">Zomedica Taps Into Costa Rica With Strategic Partnership With SIRE Veterinario</a>
The agreement not only expands PulseVet distribution to more European countries but also adds the TRUFORMA platform, equine eACTH and Cortisol assays, and the upcoming equine Insulin assay to Grovet&#8217;s product offerings.
Koen Schmitz-Managing Director of Grovet said, &#8220;We only partner with companies whose products are rooted in scientific studies, and all of Zomedica&#8217;s products we are carrying are exactly just that, rooted in science and steeped in research.&#8221;
Brandon Marino, Senior Director of Global Channels for Zomedica, said, &#8220;Grovet has been a great partner to Zomedica for the equine PulseVet product line over the last several years, and they were the perfect partner to help expand the reach of our TRUFORMA equine platform within Europe.&#8221;&nbsp;
Price Action: ZOM shares are up 2.53% at $0.1337 at the last check Thursday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/41163538" target="_blank" rel="noreferrer noopener">Starbucks Invests In Future-Proof Coffee: New Farms In Latin America And Beyond To Tackle Climate Challenges</a></li>
</ul>

Equities

News

Small Cap

Zomedica Strengthens European Foothold With Grovet Partnership, Expanding PulseVet And TRUFORMA Reach

TD Cowen analyst Oliver Chen maintains Levi Strauss (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) with a Buy and lowers the price target from $25 to $23.

Price Target

Analyst Ratings

LEVI

TD Cowen Maintains Buy on Levi Strauss, Lowers Price Target to $23

The demand for GLP-1 agonists, including Novo Nordisk A/S&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Ozempic and Wegovy (semaglutide), a class of drugs used to manage diabetes and obesity, continues to grow.
Though initially developed for type 2 diabetes, GLP-1s have gained attention for their effectiveness in weight management. The FDA approval expanded use for <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37567088/novo-nordisks-game-changer-fda-approves-weight-loss-sensation-wegovy-for-heart-health-potential-i" rel="noreferrer noopener">cardiovascular indication for Wegovy</a> and potential future applications for chronic kidney disease and non-alcoholic steatohepatitis (NASH) further underscores the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41034046/popular-ozempic-may-have-new-use-as-semaglutide-drugs-linked-to-reduced-overdose-risk-in-diabetic" rel="noreferrer noopener">promise of these treatments</a>.
The Forbes report <a target="_blank" href="https://www.forbes.com/sites/joshuacohen/2024/10/02/weight-loss-from-glp-1-drugs-not-as-robust-in-real-world-settings/" rel="noreferrer noopener">adds</a> that real-world evidence shows that weight loss from GLP-1 usage may not align with the outcomes seen in clinical trials.
A study published in the Journal of the American Medical Association (JAMA) revealed that patients, on average, achieved only a 3.7% weight reduction after one year on the drugs—lower than the results reported in controlled trials.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40986953/novo-nordisk-ceo-to-face-senate-scrutiny-over-high-ozempic-and-wegovy-prices-hearing-scheduled-on" rel="noreferrer noopener">Novo Nordisk CEO To Face Senate Scrutiny Over High Ozempic And Wegovy Prices, Hearing Scheduled On Tuesday</a>.
While patients have high expectations for substantial weight loss, the findings suggest that most individuals did not experience the same degree of benefit as seen in clinical settings.
However, those who persisted with GLP-1 therapy saw results comparable to those in clinical trials.
In another study published in 2023, researchers observed a modest average weight loss of 2.2% over 72 weeks among type 2 diabetes patients on GLP-1s.
Additionally, a pre-print analysis this year found that the real-world effectiveness of GLP-1s was less pronounced than in randomized controlled trials.
This difference underscores the challenge of replicating clinical trial success in everyday medical settings, where factors like medication adherence and real-life conditions are involved.
Persistence with GLP-1 medications is a significant issue. Forbes reported that only 15% of patients who started GLP-1 drugs for weight loss remained on them after two years, citing Prime Therapeutics, a pharmacy benefit manager.
Discontinuation rates were high, with just 29% continuing treatment after one year and a mere 15% after two years.
Other studies, including findings from Blue Cross Blue Shield, show that many patients stop GLP-1 therapy early, often within the first month, before achieving meaningful weight loss.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41166018/medicare-drug-price-negotiation-program-gets-final-guidance-for-second-cycle-1-5b-savings-expecte" target="_blank" rel="noreferrer noopener">Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected</a>.</li>
</ul>
Photo via Shutterstock

Biotech

Large Cap

Health Care

Media

General

Popular Weight Loss Drugs Like Ozempic Show Gap Between Clinical Trial Promises And Real-World Use, Study Reveals

Barclays analyst Betty Jiang maintains Chevron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) with a Overweight and lowers the price target from $185 to $168.

Barclays Maintains Overweight on Chevron, Lowers Price Target to $168

Barclays analyst Betty Jiang maintains California Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRC#NYSE">CRC</a>) with a Equal-Weight and raises the price target from $55 to $57.

Barclays Maintains Equal-Weight on California Resources, Raises Price Target to $57

WIIM

BWXT

BWX Technologies shares are trading higher after Deutsche Bank maintained a Buy rating on the stock and raised its price target from $113 to $129.

Levi Strauss &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) shares are trading lower Thursday after the company posted worse-than-expected third-quarter <a href="https://www.benzinga.com/news/earnings/24/10/41151280/levi-strauss-co-stock-falls-after-mixed-q3-results-eps-beat-revenues-miss">revenue on Wednesday</a>.
The Details:
Levi Strauss reported quarterly revenue of $1.516 billion, below consensus estimate of $1.55 billion, due in part to the exit of its Denizen business. The company also revealed it&#8217;s <a href="https://www.benzinga.com/markets/equities/24/10/41156870/levi-strauss-considers-dockers-sale-what-this-means-for-the-iconic-denim-brand">considering a sale</a> of its Dockers brand. 
"We are narrowing our focus to realize the full potential of the Levi's brand as well as accelerate Beyond Yoga. Accordingly, we are undertaking an evaluation of strategic alternatives for the global Dockers business," CEO Michelle Gass said during a post-earnings call.
Read Next: <a href="https://www.benzinga.com/news/24/10/41152629/what-happened-with-accenture-stock-today">What Happened With Accenture Stock Today?</a>
Levi Strauss issued fiscal 2024 earnings guidance with its midpoint below estimates. The company expects earnings of between $1.17 and $1.27 per share for the year, versus the $1.25 estimate.&nbsp;
Stifel analyst Drew Crum maintained a Buy rating and lowered the price target from $28 to $25 following the print. Telsey Advisory Group maintained its Outperform rating and $26 price target.
<h3 class="wp-block-heading">Should I Sell My LEVI Stock?</h3>
Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.
Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.
Shares of Levi Strauss have gained 48.15% year to date. This compares to the average annual return of -3.24%, meaning the stock has outperformed its historical averages. Investors can compare a stock's movement to its historical performance to gauge whether this is a normal movement or a potential trading opportunity. 
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Levi Strauss stock currently has an RSI of 56.58, indicating neutral conditions.
For analysis tools, charting data and access to exclusive stock news, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a> 
LEVI Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Levi Strauss &amp; Co shares are down 7.22% at $19.54 at the time of publication Thursday.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41122476/whats-going-on-with-microstrategy-stock">What&#8217;s Going On With MicroStrategy Stock?</a></li>
</ul>
Image: Shutterstock&nbsp;

Earnings

Movers

What's Going On With Levi Strauss Stock After Earnings?

Barclays analyst Christine Cho maintains Array Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) with a Overweight and lowers the price target from $11 to $10.

ARRY

Barclays Maintains Overweight on Array Technologies, Lowers Price Target to $10

TD Cowen analyst Helane Becker maintains Allegiant Travel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGT#NASDAQ">ALGT</a>) with a Hold and raises the price target from $33 to $42.

ALGT

TD Cowen Maintains Hold on Allegiant Travel, Raises Price Target to $42

Asset Sales

Management

Helix Energy Solutions Said To Explore Options, Including Sale

Barclays analyst Betty Jiang maintains APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) with a Equal-Weight and lowers the price target from $35 to $30.

Barclays Maintains Equal-Weight on APA, Lowers Price Target to $30

STLA

Stellantis shares are trading lower after Barclays downgraded the stock from Overweight to Equal-Weight. On Wednesday, the FCA reported a year-over-year decrease in total U.S. sales.

Barclays analyst Betty Jiang maintains Antero Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AR#NYSE">AR</a>) with a Equal-Weight and lowers the price target from $32 to $30.

Barclays Maintains Equal-Weight on Antero Resources, Lowers Price Target to $30

TD Cowen analyst Thomas Fitzgerald maintains American Airlines Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) with a Hold and raises the price target from $7 to $9.

TD Cowen Maintains Hold on American Airlines Gr, Raises Price Target to $9

Rezolve AI Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) shares are trading higher Thursday after the company announced a strategic partnership with Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) to enhance global retail innovations <a href="https://www.benzinga.com/news/24/09/41032594/whats-going-on-with-rezolve-ai-limited-today">using AI-powered commerce solutions.</a>
What To Know: Rezolve AI and Microsoft have formed a collaboration to provide advanced digital engagement capabilities to retailers. Rezolve AI's Brain Suite—which includes Brain Commerce, Brain Checkout, and Brain Assistant—will be hosted on Microsoft Azure and available through the Azure Marketplace.
The partnership includes extensive Go-to-Market (GTM) and co-sell support from Microsoft for five years. This includes marketing, sales support through Microsoft&#8217;s 35,000 incentivized sellers, and technical assistance from the Microsoft AI Cloud Partner Program.
What Else: Rezolve AI&#8217;s Brain Suite aims to address common eCommerce challenges such as reducing cart abandonment and improving customer engagement with AI capabilities available in 95 languages. The solutions are designed to enhance operational efficiency and provide a quick return on investment (ROI).
RZLV And MSFT Price Action: Rezolve shares were up by 29.7% at $8.52 and Microsoft shares were up by 0.01% at $417.09 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga pro.</a>
See Also:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41166018/medicare-drug-price-negotiation-program-gets-final-guidance-for-second-cycle-1-5b-savings-expecte">Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected</a></li>
</ul>
Image via Unsplash.

MSFT

RZLV

Rezolve AI Shares Surge On Microsoft Partnership Announcement: What You Need To Know

Global

GILD

Gilead Donates Remdesivir For Emergency Use In Response To Marburg Virus Disease In Rwanda; Says It Will Donate Approximately 5,000 Vials Of Remdesivir To Rwanda Medical Supply

Rosenblatt analyst Mike Genovese maintains Calix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) with a Buy and maintains $45 price target.

CALX

Rosenblatt Maintains Buy on Calix, Maintains $45 Price Target

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) mining stocks CleanSpark Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) and Riot Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) are seeing increased attention Thursday after the companies released <a href="https://www.benzinga.com/pressreleases/24/10/n41163693/cleanspark-releases-september-2024-bitcoin-mining-update">mining updates for September</a>.
What&#8217;s Going On With CLSK: CleanSpark said it mined 493 Bitcoin in September, up from 478 in August. The company has now mined a total of 5,079 Bitcoin year-to-date, bringing its total&nbsp;Bitcoin&nbsp;holdings up to 8,049 as of Sept. 30.
CleanSpark sold 2.5&nbsp;bitcoin last month at an average price of approximately&nbsp;$58,287&nbsp;per&nbsp;coin. The company had an average hashrate of 23.4 EH/s for the month, resulting in an average of 16.43&nbsp;Bitcoin&nbsp;mined daily. CleanSpark noted that it had a peak hashrate of 27.6 EH/s in September before Hurricane Helene impacted its operations at the end of the month.
CleanSpark noted that it experienced no material damage to any site infrastructure and is not aware of any material losses related to its mining servers. As of&nbsp;Oct. 2, all but 45 MW of power had been restored to the company&#8217;s sites. The remaining 45 MW is expected to be restored &#8220;in the coming days.&#8221;
&#8220;Our expansion efforts have not slowed down, and we are actively racking miners at newly acquired sites and at our existing facilities as part of our fleet upgrade plan,&#8221; said Zach Bradford, CEO of CleanSpark.
Through these efforts, we expect to reach 30 EH/s during&nbsp;October 2024. Looking ahead to fiscal year 2025, we are positioned to rapidly achieve our forecasted growth to 50 EH/s and beyond. We look forward to providing further updates on 2025 in the coming weeks.&#8221;
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41150059/bitcoin-ethereum-dogecoin-continue-downward-trend-range-deviation-or-bearish-retest-wonder">Bitcoin, Ethereum, Dogecoin Continue Downward Trend: &#8216;Range Deviation Or Bearish Retest?,&#8217; Wonders Technical Trader</a>
What&#8217;s Going On With RIOT: Riot Platforms also announced its mining metrics for September on Thursday. Riot said it mined 412 Bitcoin last month, up 28% from 322 in August. 
&#8220;This increase in production was driven by an increase in average operating hash rate across all our facilities and was achieved despite periodic curtailment that took place through our participation in the final month of ERCOT&#8217;s Four Coincident Peak (4CP) program for 2024, whereby we paused mining operations during periods of high demand on the grid,&#8221; said Jason Les, CEO of Riot. 
Riot had an average operational hashrate of 19.5 EH/s during the month, up from 14.5 EH/s in August. 
&#8220;We are excited about the results we are seeing from our growing hash rate and operational improvements, which are directly translating into increased production and improved efficiency. Following the completion of our third 100 MW building, Building B1, at our Corsicana Facility during the month, we achieved a total deployed hash rate capacity of 28.2 EH/s,&#8221; Les said.
CLSK, RIOT Price Action: At the time of publication, <a href="http://benzinga.com/quote/clsk">CleanSpark shares</a> were down 1.93% at $8.62 and <a href="http://benzinga.com/quote/riot">Riot shares</a> were down 0.28% at $7.28, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

CLSK

RIOT

What's Going On With Bitcoin Mining Stocks CleanSpark, Riot Platforms?

In the current market session, Estee Lauder Cos Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) share price is at $95.22, after a 1.96% decrease. Over the past month, the stock went up by 5.76%, but over the past year, it actually decreased by 34.42%. With good short-term performance like this, and questionable long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.

<img src="https://www.benzinga.com/files/images/story/2024/1727968597_0.png" alt="Past Year Chart" />

<h3>Estee Lauder Cos P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of 50.26 in the Personal Products industry, Estee Lauder Cos Inc. has a higher P/E ratio of 89.93. Shareholders might be inclined to think that Estee Lauder Cos Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1727968597_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

A Look Into Estee Lauder Cos Inc's Price Over Earnings

Bilibili Inc &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>) shares are trading lower by 9.44% to $26.86 Thursday morning, pulling back following a 90% surge over the past month, which was fueled by mounting optimism around China&#8217;s aggressive <a href="https://www.benzinga.com/news/24/10/41165162/china-stocks-are-cooling-off-thursday-whats-going-on">stimulus measures</a> aimed at reviving its sluggish economy.
Shares of major Chinese tech companies, including Alibaba, Baidu and JD.com, also experienced declines as concerns over escalating geopolitical tensions in the Middle East dampened investor sentiment.
What To Know: Bilibili, a popular video-sharing platform with a focus on anime, gaming and youth-centric content, has become one of China's leading online entertainment companies. It caters primarily to Gen Z and millennial users, offering a mix of user-generated content, live streaming, and mobile games. 
Despite this strong market position and a recent uptick in its stock price, driven by China&#8217;s recent stimulus actions, the company remains vulnerable to broader market movements and external risks.
Chinese markets reacted negatively on Thursday, as investors grew cautious amid fears of a potentially expanding conflict in the Middle East. The resulting uncertainty, especially regarding energy prices and global supply chains, has created concerns for emerging markets like China.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41166146/would-bitcoin-drop-if-a-war-in-the-middle-east-breaks-out-yes-but-theres-a-catch">Would Bitcoin Drop If A War In The Middle East Breaks Out? Yes, But There&#8217;s A Catch</a>
An elevated oil risk premium could hurt China's economic outlook, as it is heavily reliant on imported energy. In turn, this may affect consumer confidence and spending, which are crucial for platforms like Bilibili, where advertising revenue and in-app spending are sensitive to broader economic conditions.
What Else: Additionally, while China's recently announced measures—such as mortgage refinancing and fiscal spending to stimulate growth—have provided a short-term boost to tech stocks, the sustainability of this recovery remains a question mark. 
Bilibili, like other Chinese tech companies, has been navigating a challenging landscape over the past year, facing headwinds from China's regulatory tightening on technology and entertainment sectors, as well as weakened advertising demand.
Read Also: <a href="https://www.benzinga.com/news/24/10/41159016/port-strike-enters-day-3-economist-warns-of-meaningful-impact-if-standoff-prolongs-food-beverages-li">Port Strike Enters Day 3: Economist Warns Of &#8216;Meaningful&#8217; Impact If Standoff Prolongs, Food &amp; Beverages Likely First To Feel The Pinch</a>
<h2 class="wp-block-heading">How To Buy BILI Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Bilibili&#8217;s case, it is in the Communication Services sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, BILI has a 52-week high of $31.77 and a 52-week low of $8.80.

BILI

Why Bilibili Stock Is Volatile Today

In a report released today, Kenneth Wong from Oppenheimer maintained a Hold rating on BigCommerce Holdings (BIGC – Research Report). The company's ...

BigCommerce Holdings (BIGC) Receives a Hold from Oppenheimer

In a report released today, J. Parker Lane from Stifel Nicolaus maintained a Buy rating on BigCommerce Holdings (BIGC – Research Report), with a pr...

Stifel Nicolaus Remains a Buy on BigCommerce Holdings (BIGC)

In a report released today, Justin Patterson from KeyBanc maintained a Hold rating on BigCommerce Holdings (BIGC – Research Report). The company's ...

KeyBanc Sticks to Their Hold Rating for BigCommerce Holdings (BIGC)

Barclays analyst Raimo Lenschow assigned a Hold rating to BigCommerce Holdings (BIGC – Research Report) today and set a price target of $7.00. The ...

Barclays Gives a Hold Rating to BigCommerce Holdings (BIGC)

BigCommerce: An Unbearable Slowdown

BigCommerce appoints Travis Hess as CEO

BigCommerce Holdings ( ($BIGC) ) has issued an update. BigCommerce Holdings, Inc. has undergone a significant leadership restructuring, with Brent ...

BigCommerce Leadership Shake-Up and Growth Strategy Focus

BigCommerce Holdings (BIGC) Receives a Hold from Barclays

BigCommerce Holdings (BIGC – Research Report), the Technology sector company, was revisited by a Wall Street analyst yesterday. Analyst Koji Ikeda ...

BigCommerce Sell Rating: Leadership Changes and Sluggish Growth Outlook

Analyst Scott Berg from Needham maintained a Buy rating on BigCommerce Holdings (BIGC – Research Report) and keeping the price target at $14.00. Sc...

New Leadership, Renewed Growth: BigCommerce's Path Forward Under CEO Travis Hess

BIGC

Press Releases

BigCommerce Announces Second Quarter 2024 Financial Results

Global Footwear Retailer Soletrader Unveils High-Performance Headless Ecommerce Site Using BigCommerce

Leading UK Sporting Goods Retailer SportsShoes Launches Composable Commerce Site on BigCommerce

BigCommerce to Host Sell-side Analyst Q&A Session At Upcoming BigSummit

BigCommerce Announces 2024 Customer Award Winners

The Next Big Thing: BigCommerce Strengthens Enterprise Capabilities with Next Generation Composable Commerce, B2B Solutions, Omnichannel Integrations, AI and More

Comments

BigCommerce Holdings

Intérêt court

BigCommerce Holdings (NASDAQ:BIGC) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL